Compare AbbVie Inc (ABBV) vs Crown Castle International Corp (CCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Crown Castle International Corp — how do they compare? AbbVie Inc trades at $249.99 (market cap $438.19B), while Crown Castle International Corp trades at $73.76 (market cap $31.32B). The key difference: AbbVie Inc is far larger — about 14× Crown Castle International Corp's market cap, and Crown Castle International Corp pays the higher dividend (5.77%). Which is the better fit depends on your goals.
| ABBV | CCI | |
|---|---|---|
Market Cap | $438.19B | $31.32B |
Sector | Health | Real Estate |
52-Week High | $263.58 | $103.79 |
52-Week Low | $197.38 | $73.61 |
Enterprise Value | $502.45B | $53.68B |
Dividend Yield | 2.79% | 5.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.
Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.
Crown Castle (CCI) trades at $75.59, up 0.89% on the day, but technical indicators signal a bearish trend with the stock near recent lows. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, while revenue has declined from $7.0B in 2023 to $4.26B in 2025. Analyst consensus is split evenly between Buy and Hold with a $95.29 price target, suggesting potential upside. Recent news highlights strategic shifts, including the sale of its fiber business and a focus on U.S. tower operations.
The outlook for CCI hinges on execution of its pure-play tower strategy amid high debt levels and competitive pressures. Investment appeal lies in its 5.5% dividend yield and discounted valuation, but risks include declining revenue, negative shareholder equity, and sensitivity to interest rates. Wall Street sees value if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Crown Castle International Corp
Crown Castle International owns and leases roughly 40,000 cell towers in the United States. It also owns more than 85,000 route miles of fiber. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. The company's fiber is primarily leased by wireless service providers to set up small-cell network infrastructure and by enterprises for their internal connection needs. Crown Castle's towers and fiber are predominantly located in the largest U.S. cities. The company has a very concentrated customer base, with more than 70% of its revenue coming from the big three U.S. mobile carriers. Crown Castle operates as a real estate investment trust.
Read more on CCI →
